Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.

Journal Article (Journal Article)

We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.

Full Text

Duke Authors

Cited Authors

  • Kilgore, JT; Becken, B; Varga, MG; Parikh, S; Prasad, V; Lugo, D; Chang, Y-C

Published Date

  • September 17, 2020

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 486 - 489

PubMed ID

  • 31362308

Pubmed Central ID

  • PMC7495908

Electronic International Standard Serial Number (EISSN)

  • 2048-7207

Digital Object Identifier (DOI)

  • 10.1093/jpids/piz050


  • eng

Conference Location

  • England